About Nektar
Nektar is a company based in San Francisco (United States) founded in 1990.. The company has 61 employees as of December 31, 2024. Nektar has completed 1 acquisition, including Aerogen. Nektar offers products and services including REZPEG, PEG-CSF1, and TNFR-2. Nektar operates in a competitive market with competitors including Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter San Francisco, United States
- Employees 61 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nektar Therapeutics
-
Annual Revenue
$98.43 M9.22as on Dec 31, 2024
-
Net Profit
$-118.96 M56.91as on Dec 31, 2024
-
EBITDA
$-128.73 M0.68as on Dec 31, 2024
-
Latest Funding Round
$30 M (USD), Post-IPO
Mar 04, 2024
-
Investors
Astrazeneca
& 2 more
-
Employee Count
61
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nektar
Nektar is a publicly listed company on the NASDAQ with ticker symbol NKTR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nektar
Nektar offers a comprehensive portfolio of products and services, including REZPEG, PEG-CSF1, and TNFR-2. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets immune pathways for autoimmune disorder treatment.
Modulates immune responses for inflammatory conditions.
Advances treatments for chronic inflammatory diseases.
Unlock access to complete
Unlock access to complete
Leadership Team
30 people
Finance and Accounting
9 people
Software Development Team
9 people
Product Management Team
7 people
Senior Team
6 people
Legal and Compliance
5 people
Human Resources and Administration
5 people
Scientist Team
5 people
Unlock access to complete
Funding Insights of Nektar
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $30.0M
- First Round First Round
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Post-IPO - Nektar | Valuation |
investors |
|
| Mar, 2019 | Amount | Post-IPO - Nektar | Valuation |
investors |
|
| Apr, 2018 | Amount | Post-IPO - Nektar | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nektar
Nektar has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Astrazeneca, BB Biotech and NEA. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Pharmaceutical and biologics products are developed and distributed worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nektar
Nektar has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Aerogen. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vibrating mesh nebulizers are manufactured for aerosol drug delivery.
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Nektar
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nektar Comparisons
Competitors of Nektar
Nektar operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nektar
Frequently Asked Questions about Nektar
When was Nektar founded?
Nektar was founded in 1990 and raised its 1st funding round 21 years after it was founded.
Where is Nektar located?
Nektar is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
How many employees does Nektar have?
As of Dec 31, 2024, the latest employee count at Nektar is 61.
What is the annual revenue of Nektar?
Annual revenue of Nektar is $98.43M as on Dec 31, 2024.
What does Nektar do?
Founded in 1990 and based in San Francisco, United States, the company operates in the biotechnology sector. Drug candidates are developed through PEGylation and polymer conjugate technologies to address cancer, pain, anti-infectives, anti-viral, and immunological conditions. The pipeline features NKTR-358 for autoimmune diseases, Bempegaldesleukin for viral indications, and various oncology programs.
Who are the top competitors of Nektar?
Nektar's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Nektar offer?
Nektar offers REZPEG, PEG-CSF1, and TNFR-2.
Is Nektar publicly traded?
Yes, Nektar is publicly traded on NASDAQ under the ticker symbol NKTR.
How many acquisitions has Nektar made?
Nektar has made 1 acquisition, including Aerogen.
Who are Nektar's investors?
Nektar has 3 investors. Key investors include Astrazeneca, BB Biotech, and NEA.
What is Nektar's ticker symbol?
The ticker symbol of Nektar is NKTR on NASDAQ.